Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: A case report

Gynecological Endocrinology

Volumn 29, Issue 3, 2013, Pages 219-221

  Nucera, Giuseppe ^a   Mandato, Vincenzo Dario ^a   Gelli, Maria Carolina ^b   Palomba, Stefano ^a   La Sala, Giovanni Battista ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Endometrial cancer; Fertility; GnRH a; IVF; LNG IUD

Indexed keywords

FOLLITROPIN; GONADORELIN AGONIST; LEUPRORELIN; LEVONORGESTREL;

ADULT; ARTICLE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CURETTAGE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLOW UP; HUMAN; HYSTERECTOMY; INFERTILITY THERAPY; INTRAUTERINE CONTRACEPTIVE DEVICE; OOCYTE RETRIEVAL; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; UTERINE TUBE OCCLUSION;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, ENDOMETRIOID; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FERTILITY PRESERVATION; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; INTRAUTERINE DEVICES, MEDICATED; LEUPROLIDE; LEVONORGESTREL; NEOPLASM STAGING; PREGNANCY; REMISSION INDUCTION; TERM BIRTH;

EID: 84874293475     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.738726     Document Type: Article

References (10)

1. Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ. Contemporary management of endometrial cancer. Lancet 2012;379:1352-1360.
2. Yang YC, Wu CC, Chen CP, Chang CL, Wang KL. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol 2005;99:287-293.
3. Gadducci A, Spirito N, Baroni E, Tana R, Genazzani AR. The fertilitysparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: A debated therapeutic option. Gynecol Endocrinol 2009;25:683-691.
4. Chiva de Agustín L, Lapuente Sastre F, Corraliza Galán V, Granados Galainena L, González Martín A, González Cortijo L, Carballo González N. Conservative management of patients with early endometrial carcinoma: A systematic review. Clin Transl Oncol 2008;10:155-162.
5. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: A systematic review. Gynecol Oncol 2012;125:477-482.
6. Minig L, Franchi D, Boveri S, Casadio C, Bocciolone L, Sideri M. Progestin intrauterine device and GnRH analogue for uterussparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol 2011;22:643-649.
7. Elizur SE, Beiner ME, Korach J, Weiser A, Ben-Baruch G, Dor J. Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma. Fertil Steril 2007;88:1562-1567. (Pubitemid 350225705)
8. Rasool N, Rose PG. Fertility-preserving surgical procedures for patients with gynecologic malignancies. Clin Obstet Gynecol 2010;53:804-814.
9. Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril 2010;93:1286-1289.
10. Ørbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111:68-73.